
Search ReportLinker
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Sam
+1 917 267 7886

... To production interruptions and diminished capacity Economic choices are made where older, less profitable drugs are eliminated as new generics come to market By year-end 2012, we will see $34b in new ...
... Years is not necessarily less than the increase in life expectancy. Since the lifetime risk of being diagnosed with cancer is about 40%, the 1978-2004 increase in the lagged stock of cancer drugs increased the life ...
... B ........................................................................................................ hepatitis b (vaccine) hib ................................................................................... Haemophilus influenzae b (vaccine) hic ...
United States
France
Spain
PharmaPoint: HIV - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: HIV - US Drug Forecast and Market Analysis to 2022?. Human Immunodeficiency ...
PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022?. Epilepsy ...
PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022?. ...
Reportlinker.com © Copyright 2013. All rights reserved.